Wholesale
Athena

Memic Innovative Surgery Ltd

Early Stage Capital

Register Interest

WARNING

The law normally requires people who offer financial products to give information to investors before they invest. This information is designed to help investors make an informed decision.

If you are an accredited investor under the definition of that term in Rule 501(a) of Regulation D of the US Securities Act of 1933, the usual rules do not apply to offers of financial products made to you. As a result, you may not receive a complete and balanced set of information.

You will also have fewer other legal protections for these investments. Ask questions, read all documents carefully, and seek independent financial advice before committing yourself.

Transaction Size
USD 60,000,000.00
Share Price
USD 1.00
Minimum Investment
USD 50,000.00
Issue Type
Early Stage Capital
Sector
Health Care

An opportunity exists for wholesale investors to register interest to invest in Memic Innovative Surgery Limited (“Memic”). 

Background

Memic is seeking USD60m on a most recent pre-money valuation of USD150m, with proceeds to be applied to sales & marketing, R&D/ IP, clinical development & regulatory, manufacturing scale up and general costs

Memic has set out to transform robot-assisted surgery, with proprietary technology that has the potential to far surpasses today’s best solutions. This has been delivered by Memic’s Hominis™ which can provide unprecedented access and manoeuvrability. Its surgical platform features miniature, humanoid-shaped robotic arms with human dexterity, superhuman flexibility, and 360˚ articulation for various access configurations. It is dramatically smaller, more versatile and less costly than current robotic platforms and the technology opens up a host of minimally-invasive procedures that until now have been off-limits to robot-assisted surgery.

Some pipeline indications include abdominal single and multi-port surgery, as well as procedures performed in a trans-oral approach. Memic envisions a near future where numerous indications – and millions of patients – will benefit from these disruptive capabilities.

People

Maurice R. Ferré, MD has been appointed as chairman of Memic’s board of directors, following the company’s latest USD10m investment round. Signing on as a private investor, Mr. Ferré has over 20 years of experience in the medical device industry. He currently serves as CEO and chairman of the board of directors of INSIGHTEC, which delivers incisionless surgery using focused ultrasound guided by MRI.

A longtime innovator and entrepreneur, Dr. Ferré has founded and managed several world-leading companies in the field of precision, robotic, and image-guided surgery, making him ideally suited to chair Memic’s unique robot-assisted surgical technology.

Regulatory Approval

The company is in a process seeking the appropriate FDA approvals – the capital raise is subject to those approvals being received.

An overview of the company and its initiatives can be accessed in Documents as can a timeline of the FDA approval process.

Summary of Investment highlights:

  • Transformational robotic surgery technology
  • Technology developed and will be available at considerably lower cost to alternatives
  • Proven, successful leadership team with track record of successfully developing and commercialising medical technology
  • Capital invested subject to FDA approval

To visit Memic’s website click here.

The PPM will be made available on registration of interest. 

Memic Company Presentation - June 2020
July 5, 2020
5/7/2020
Memic Regulatory Overview - December 2019
July 5, 2020
5/7/2020

Join our Issuer newsletter

Our quarterly Issuer newsletter is for partners, businesses and anyone interested in what we’re up to, platform updates and market commentary. To sign up to the Investor newsletter for marketplace offers click here.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.